Peptide Therapeutics Market Size, Trends, Shares, Insights and Forecast – 2018-2026

 Several peptide therapeutics are used as replacement therapies in order to supplement peptide hormones when endogenous levels are inadequate or absent. Insulin and adrenocorticotrophic hormone (ACTH) are peptides isolated from natural sources, whereas oxytocin and vasopressin are synthetic peptides.

The global Peptide Therapeutics Market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.

Global Peptide Therapeutics Market: Drivers

Increasing adoption of peptide therapeutics is expected to aid in growth of the global peptide therapeutics market over the forecast period. Peptides therapeutics are typically associated with lower production complexity compared with protein-based-biopharmaceuticals. This in turn results in lower production costs, which increases adoption of peptides therapeutics compared to small molecules and biopharmaceuticals.

Global Peptide Therapeutics Market: Opportunities

Development of multifunctional peptides and conjugates is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2019, researchers from University of Milan reported that the polypeptide lunasin derived from bioactive food offered hypocholesterolemic, antioxidant, and anti-inflammatory properties and can be effective in prevention of cardiovascular disease.

Global Peptide Therapeutics Market: Restraints

Therapeutic peptides have low membrane permeability and are prone to hydrolysis and oxidation, which is expected to hinder growth of the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1837

Key Takeaways:

The branded sub segment in the product type segment in global peptide therapeutics market was valued at US$ 12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 at a CAGR of 9.1% during the forecast period.

Branded medications in the peptide therapeutics market have extensive patent protections and preferred by the physicians in developed as well as emerging economies. Moreover, branded medications are costly as compared to generic peptide therapeutics.

The cancer sub segment in applications segment held dominant position in the global peptide therapeutics market in 2018, accounting for 34.3% share in terms of value, followed by metabolic disorders and central nervous system disorders, respectively.

Increasing prevalence of cancer is expected to create lucrative opportunities for growth of manufacturers in the market. For instance, according to the National Cancer Institute, 2016, the number of new cancer cases per year is expected to increase to 23.6 million by 2030, worldwide.

The parenteral sub segment in route of administration segment held dominant position in the global peptide therapeutics market in 20148, accounting for 70.4% share in terms of value, followed by transdermal route and mucosal route, respectively.

Vast number of parenteral peptide therapeutics have been launched in the market. These drugs are effective as the drug is directly administered in the blood stream bypassing gastrointestinal tract.

Market Trends

The market is witnessing increasing adoption of peptide therapeutics for the treatment of cancer. For instance, in January 2020, IBicycle Therapeutics plc., a biotechnology that develops therapeutics based on its proprietary bicyclic peptide technology, collaborated with Cancer Research UK for funding in R&D of BT7401, a multivalent Bicycle CD137 agonist for the treatment of cancer.

Major players in the market are focused on collaborating with universities for R&D of new peptide therapeutics. For instance, in 2018, Sapience Therapeutics, Inc., a biotechnology company focused on R&D in peptide therapeutics, collaborated with the University of Bath to discover new therapeutic agents.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837

Regulations

Europe

The medicines regulatory authorities of the Member States, or 'national competent authorities', are responsible for the authorisation of medicines available in the EU that do not pass though the centralised procedure.

For clinical trials, European Medicines Agency maintains only EUDRACT and EUDRAVigilance database. The National agency of each country is responsible for conducting the trial.

CHMP or Committee for Medicinal Products for Human use assess the product for marketing approval in EU

In EU, biologic is wide umbrella term that includes peptides

Non-clinical studies are carried out according to ICH-S6 guidelines

There is a centralised MAA procedure; however, biologics are also approved at member state level

Global Peptide Therapeutics Market: Competitive Landscape

Major players operating in the global peptide therapeutics market include, AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.

Global Peptide Therapeutics Market: Key Developments

January 2020: Cybrexa Therapeutics, a privately-held biotechnology company focused on development of next-generation tumor-targeted cancer therapies, announced CBX-12 (alphalex exatecan) as the new lead development program. The Cybrexa alphalex technology platform consists of a pHLIP peptide, linker, and small molecule anti-cancer agent.

January 2020: Protagonist Therapeutics, Inc. announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc., for co-development and commercialization of PTG-200, an oral, gut-restricted IL-23 receptor antagonist and second generation peptides for the treatment of inflammatory bowel disease.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1837

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

Peptide Therapeutics Market to surpass US$ 45.0 billion by 2026: CMI

The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Peptide therapeutics have wide range of applications in medicine and biotechnology and therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1) agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative market growth, as Victoza from Novo Nordisk, is the most prominent member of the class, reaching blockbuster status. Moreover, main area currently driving the growth of peptide therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore, peptide therapeutics are in clinical testing for infectious diseases and inflammation.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1837

Key players in the peptide therapeutic market are engaged in expanding market share through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity (dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA), approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Peptide therapeutics market is projected to witness lucrative growth over the forecast period, owing to the various in-organic growth strategies implemented by key manufacturing players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.

Furthermore, in September 2015, PeptiDream Inc. developed a multi-target discovery and optimization collaboration with Sanofi S.A. Under this agreement, PeptiDream will use their proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi S.A. Furthermore, Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

Browse 26 Market Data Tables and 45 Figures spread through 189 Pages and in-depth TOC on "Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others) - Global Forecast to 2026"

To know the latest trends and insights related to peptide therapeutics market, click the link below: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837

In December 2017, Entrega collaborated with Eli Lilly and Company to make advancement in Entrega’s proprietary peptide delivery technology. Under the agreement, Entrega will receive the US$ 5 million in equity and research in funding from Eli Lilly to investigate the application of Entrega’s peptide delivery technology to certain Lilly products and their therapeutic candidates.

Key takeaways of the Peptide Therapeutics Market:

• The global peptide therapeutics market is expected to expand at a CAGR of 9.1% during the forecast period (2018 – 2026), owing to increasing technological advancement in peptide therapeutics by various key players.
• Among type segment, branded therapeutic peptide is expected to witness significant growth in peptide therapeutics market, owing to increasing investment by various key manufacturers in research and development (R&D) for the development of branded or innovative peptide drugs and high prescription rate.
• Cancer holds major market share in application segment due to increasing prevalence and incidence among global population. In addition, increasing adoption of peptide therapeutics in cancer treatment, growing awareness among the patients and healthcare professionals regarding adverse effects of chemotherapy and growing need towards alternative therapeutics such as peptide-based drugs, will further drive the cancer segment of peptide therapeutics market.
• Parenteral administration holds largest market share in route of administration segment, owing to easy and increased absorption of peptide drugs into the patient’s body. According to the Drug Discovery Today, January 2015 data findings, majority (75%) of the peptide drugs are administrated by parenteral route.
• Some of the major players operating in global peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., and Amgen Inc.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.